Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine
Status:
Completed
Trial end date:
1990-05-01
Target enrollment:
Participant gender:
Summary
To determine if the pharmacokinetics of high doses of zidovudine (AZT) (that is, how fast AZT
reaches the blood, what concentration of AZT is attained in the blood, and how long AZT
remains in the blood) changes from day to day in the same patient. Also to determine whether
the pharmacokinetics of AZT is changed when trimethoprim/sulfamethoxazole (SMX/TMP) is given
at the same time, or whether the pharmacokinetics of SMX/TMP is altered by AZT given at the
same time.
AZT has been effective in treating HIV infection in some patients with AIDS, and SMX/TMP is
an antibiotic combination which is useful in preventing or treating Pneumocystis carinii
pneumonia (PCP). It is important to know how drugs interact in patients because addition of a
second drug may change the speed at which a drug is eliminated from the body, and cause
increased toxic effects or decreased therapeutic effects.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination Zidovudine